Rating Change
RBC Capital reiterated its Outperform rating on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) on October 05, 2026.
reiterateNASDAQ:NAMS
RBC Capital Reiterates Outperform Rating on NewAmsterdam Pharma Company N.V. (NAMS)
RBC Capital reiterated its Outperform rating on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) on October 05, 2026.
At publication ·
What changed
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) · reiterate
- Firm
- RBC Capital
- Rating
- Outperform to Outperform
- Price at event
- $23.09
- Market capitalization
- $4.1B
At a glance
Key takeaways
- RBC Capital reiterated an Outperform rating on NewAmsterdam Pharma (NAMS) on October 5, 2026, with the stock trading at $23.09 and a market capitalization of $4.1 billion.
Market Context
NewAmsterdam Pharma Company N.V. operates in the Healthcare sector. The stock currently trades at $23.09 with a market capitalization of $4.1B.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for NewAmsterdam Pharma Company N.V.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for NewAmsterdam Pharma Company N.V.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | RBC Capital | Outperform | N/A |
| Sep 08, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 06, 2026 | RBC Capital | Outperform | N/A |
| Jun 30, 2026 | RBC Capital | Outperform | N/A |
| Feb 19, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NAMS Stock Page
Frequently Asked Questions
What does the Outperform rating mean for NAMS?
A rating of Outperform from RBC Capital reflects the analyst's outlook on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NAMS forecast page.